Ankylosing Spondylitis Market Size

Ankylosing Spondylitis Market Size

Ankylosing Spondylitis Market size accounted for USD 5.9 billion in 2023 and is anticipated to showcase growth at 8.2% CAGR from 2024 to 2032, due to increasing prevalence of ankylosing spondylitis. The improved diagnostic techniques have led to more cases being diagnosed.

Additionally, patient education initiatives have raised awareness about the disease among both patients and healthcare providers, resulting in earlier diagnosis and timely treatment. Thus, a combination of factors, including advancements in treatment options, increasing prevalence and awareness of the disease, and improved diagnostic methods significantly contributes to the market growth.
 

Furthermore, advancements in treatment options have significantly impacted the ankylosing spondylitis market. The introduction and widespread adoption of biologic therapies, such as TNF inhibitors and IL-17 inhibitors, have transformed the management of ankylosing spondylitis by improving patient outcomes. Moreover, the development of JAK inhibitors has also provided new treatment options for patients who do not respond to conventional therapies, further driving market growth.
 

Ankylosing spondylitis (AS) is a chronic inflammatory arthritis primarily affecting the spine and sacroiliac joints, causing persistent pain, stiffness, and eventual fusion of joints. It often starts with inflammation in the lower back and can progress to other joints and ligaments, impacting mobility. Its treatment involves a comprehensive approach aimed at managing symptoms and slowing disease progression. It typically includes the use of non-steroidal anti-inflammatory drugs (NSAIDs) to reduce inflammation and pain, and biologic therapies, including TNF inhibitors and IL-17 inhibitors, targeting specific immune system pathways to control inflammation.